Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Terbutaline sulfate
Drug ID BADD_D02163
Description Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s and early 1970s.[A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088]
Indications and Usage Terbutaline is indicated for prevention and reversal of bronchospasm in patients at least 12 years old, with asthma and reversible bronchospasm associated with bronchitis and emphysema.[L32093,L32098]
Marketing Status approved
ATC Code R03CC03; R03AC03
DrugBank ID DB00871
KEGG ID D00688
MeSH ID D013726
PubChem ID 441334
TTD Drug ID D0M8RC
NDC Product Code 52584-665; 67296-1053; 0143-9746; 62135-524; 0404-9962; 24979-132; 24979-133; 0527-1318; 71872-7130; 71205-938; 51927-2765; 69826-0001; 0143-9375; 71872-7080; 72843-101; 12828-0053; 49452-7631; 62135-525; 63323-665; 0527-1311; 62991-1152; 53104-7513; 62559-721; 62559-722; 71205-939
UNII 576PU70Y8E
Synonyms Terbutaline | Asthmoprotect | Brethaire | Brethine | Bricanyl | Terbasmin | Bricanyl SA | Butaliret | Butalitab | Contimit | KWD-2019 | KWD 2019 | KWD2019 | Monovent | Taziken | Tedipulmo | Terbul | Terbutalin AL | Terbutalin Stada | terbutalin von ct | Terbutalin-ratiopharm | Terbutalin ratiopharm | Terbutaline Sulfate | Terbuturmant | Arubendol
Chemical Information
Molecular Formula C24H40N2O10S
CAS Registry Number 23031-32-5
SMILES CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anxiety19.06.02.002--
Asthenia08.01.01.001---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity vasculitis01.01.04.008; 10.02.02.017; 23.06.02.005; 24.12.04.013---
Hypertonia15.05.04.007; 17.05.02.001---
Insomnia17.15.03.002; 19.02.01.002--
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Nervousness19.06.02.003---
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Rash23.03.13.001---
Somnolence17.02.04.006; 19.02.05.003--
Tachycardia02.03.02.007---
Tremor17.01.06.002--
Vasodilatation23.06.05.006; 24.03.02.003---
Ventricular extrasystoles02.03.04.007---
Vomiting07.01.07.003--
Hepatic enzyme increased13.03.04.028---
The 1th Page    1    Total 1 Pages